Top

Published in:

Open Access 01-12-2018 | Research article

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis

Authors: Dominik Bettinger, Eleni Gkika, Michael Schultheiss, Nicolas Glaser, Sophie Lange, Lars Maruschke, Nico Buettner, Simon Kirste, Ursula Nestle, Anca-Ligia Grosu, Robert Thimme, Thomas B. Brunner

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC.

Methods

Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed.

Results

Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups.

Conclusions

SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.

Available only for authorised users

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. https://doi.org/10.1002/hep.24199.CrossRefPubMedPubMedCentral

Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55. https://doi.org/10.1136/gutjnl-2013-306627.CrossRefPubMedPubMedCentral

Clinical Practice Guidelines EASL. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019.CrossRef

Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–20. https://doi.org/10.1016/j.ctrv.2010.07.006.CrossRefPubMed

Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, et al. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol. 2013;9(4):357–64. https://doi.org/10.1111/ajco.12081.CrossRefPubMed

Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. 2017;12:116. https://doi.org/10.1186/s13014-017-0851-7.CrossRefPubMedPubMedCentral

Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for hepatocellular carcinoma: 8-year experience from a regional transplant center. J Gastrointest Cancer. 2017; https://doi.org/10.1007/s12029-017-9990-1.

Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2017;27:247–55. https://doi.org/10.1016/j.semradonc.2017.02.002.CrossRefPubMed

Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014;111:412–7. https://doi.org/10.1016/j.radonc.2014.05.002.CrossRefPubMed

10.

O’Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2012;18:949–54. https://doi.org/10.1002/lt.23439.CrossRef

11.

Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy versus TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol. 2017; https://doi.org/10.1016/j.jhep.2017.02.022.

12.

Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys. 2012;83:895–900. https://doi.org/10.1016/j.ijrobp.2011.08.032.CrossRefPubMed

13.

Bettinger D, Pinato J, Schultheiss M. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib : A Propensity Score Analysis; 2018. https://doi.org/10.1159/000490260.CrossRef

14.

Timmerman RD. An overview of Hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215–22. https://doi.org/10.1016/j.semradonc.2008.04.001.CrossRefPubMed

15.

Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:221–39. https://doi.org/10.1002/sim.CrossRef

16.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.CrossRefPubMed

17.

Mendez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: from technological evolution to improved patient care. Best Pract Res Clin Gastroenterol. 2016;30:603–16. https://doi.org/10.1016/j.bpg.2016.06.003.CrossRefPubMed

18.

Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34:452–9. https://doi.org/10.1200/JCO.2015.61.4925.CrossRefPubMed

19.

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42. https://doi.org/10.1053/jhep.2003.50047.CrossRefPubMed

20.

Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, et al. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-Centre, prospective study. Aliment Pharmacol Ther. 2017;45(8):1146–55. https://doi.org/10.1111/apt.13977.CrossRefPubMed

21.

Klein J, Dawson LA, Jiang H, Kim J, Dinniwell R, Brierley J, et al. Prospective longitudinal assessment of quality of life for liver Cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93:16–25. https://doi.org/10.1016/j.ijrobp.2015.04.016.CrossRefPubMed

22.

Dawson LA. Overview: where does radiation therapy fit in the Spectrum of liver Cancer local-regional therapies? Semin Radiat Oncol. 2011;21:241–6. https://doi.org/10.1016/j.semradonc.2011.05.009.CrossRefPubMed

23.

Mendez Romero A, Wunderink W, van Os RM, Nowak PJCM, Heijmen BJM, Nuyttens JJ, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys. 2008;70:1447–52. https://doi.org/10.1016/j.ijrobp.2007.08.058.CrossRefPubMed

24.

Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, RKS W, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol. 2017;31(13):1631–9. https://doi.org/10.1200/JCO.2012.44.1659.CrossRef

Title: Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Authors: Dominik Bettinger
Eleni Gkika
Michael Schultheiss
Nicolas Glaser
Sophie Lange
Lars Maruschke
Nico Buettner
Simon Kirste
Ursula Nestle
Anca-Ligia Grosu
Robert Thimme
Thomas B. Brunner
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4696-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Feasibility, useability and acceptability of technology-based interventions for informal cancer carers: a systematic review

Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala

Keynote webinar | Spotlight on antibody–drug conjugates in cancer